Legato Merger Corp. III (LEGT)

NYSEAMERICAN: LEGT · Real-Time Price · USD

10.72

-0.02 (-0.23%)

At close: Aug 1, 2025, 4:00 PM

10.72

0.00 (0.00%)

After-hours: Aug 1, 2025, 8:00 PM EDT

Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	May '25 May 31, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023
Selling, General & Admin	0.92	0.67	0.21
Operating Expenses	0.92	0.67	0.21
Operating Income	-0.92	-0.67	-0.21
Interest & Investment Income	9.98	8.89	-
Pretax Income	9.06	8.22	-0.21
Net Income	9.06	8.22	-0.21
Net Income to Common	9.06	8.22	-0.21
Shares Outstanding (Basic)	26	26	-
Shares Outstanding (Diluted)	26	26	-
EPS (Basic)	0.35	0.32	-
EPS (Diluted)	0.35	0.32	-
EBIT	-0.92	-0.67	-0.21

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q